Presenter of 1 Presentation
GLYCEMIC OUTCOMES IN ADULTS FROM RACIAL/EDUCATION/SOCIOECONOMIC MINORITIZED POPULATIONS WITH TYPE 1 DIABETES IN A PIVOTAL AUTOMATED INSULIN DELIVERY (AID) TRIAL
Abstract
Background and Aims
This pivotal parent study (NCT03563313) showed an overall increase in time in target range (TIR) of 11% [95%CI 9 to 14; p<0.001] favorable to AID use compared to sensor-augmented pump (SAP) therapy, which contributed to the FDA’s authorization of its commercialization. However, such technology is utilized less among Black, Indigenous, and People of Color (BIPOC) and lower socioeconomic status (SES) individuals. This study investigated improvements in glycemic outcomes for participants of different racial and SES groups while using AID vs SAP in this trial
Methods
Case summaries of participants differing in income, education, and race/ethnicity were analyzed to determine each group’s percentages of TIR (70-180mg/dL), time in hyperglycemia (>180mg/dL), and time in hypoglycemia (<70mg/dL) while using AID vs SAP therapy.
Results
The majority of participants in the trial were White and from higher income and education groups. TIR percentages using SAP compared to AID increased 18.6% for individuals making <$50,000 (7.1% of participants), compared to a 9.7% and 9.6% increase for those making $50,000-$100,000 (29.8%) and >$100,000 (61.7%), respectively. Those without (10.6% of participants) and with a bachelor’s degree (57.6%) spent 26.7% and 13.4% less time in hyperglycemia using AID, respectively. BIPOC individuals (10.6% of participants) spent 51.8% less time in hypoglycemia, whereas White individuals (87.6%) spent 43.9% less time <70 mg/dl. No group differences were significant.
Conclusions
Although BIPOC and lower SES populations were underrepresented in this trial, data indicates that these groups achieved similar glycemic outcomes compared to higher income/education and Caucasian participants showing a potential equalizing benefit from this type of technology.